Inhibitory effects of Tomivosertib in acute myeloid leukemia

Milagros Suarez; Gavin T. Blyth; Alain A. Mina; Ewa M. Kosciuczuk; Blazej Dolniak; Shira Dinner; Jessica K. Altman; Elizabeth A. Eklund; Diana Saleiro; Elspeth M. Beauchamp; Leonidas C. Platanias

doi:10.18632/oncotarget.27952

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Inhibitory effects of Tomivosertib in acute myeloid leukemia

Milagros Suarez, Gavin T. Blyth, Alain A. Mina, Ewa M. Kosciuczuk, Blazej Dolniak, Shira Dinner, Jessica K. Altman, Elizabeth A. Eklund, Diana Saleiro, Elspeth M. Beauchamp and Leonidas C. Platanias _

PDF | Full Text | How to cite | Press Release | Podcast

Oncotarget. 2021; 12:955-966. https://doi.org/10.18632/oncotarget.27952

Metrics: PDF 1451 views | Full Text 5719 views | ?

Abstract

Milagros Suarez1, Gavin T. Blyth1, Alain A. Mina1^,2, Ewa M. Kosciuczuk1^,2^,3, Blazej Dolniak1, Shira Dinner1^,2, Jessica K. Altman1^,2, Elizabeth A. Eklund1^,2^,3, Diana Saleiro1^,2, Elspeth M. Beauchamp1^,2^,3 and Leonidas C. Platanias1^,2^,3

1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

2 Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

3 Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA

Correspondence to:

Leonidas C. Platanias,

email:

[email protected]

Keywords: MNK; Tomivosertib; acute myeloid leukemia; eIF4E

Received: February 23, 2021 Accepted: April 19, 2021 Published: May 11, 2021

Copyright: © 2021 Suarez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The MAPK-interacting kinases 1 and 2 (MNK1/2) have generated increasing interest as therapeutic targets for acute myeloid leukemia (AML). We evaluated the therapeutic potential of the highly-selective MNK1/2 inhibitor Tomivosertib on AML cells. Tomivosertib was highly effective at blocking eIF4E phosphorylation on serine 209 in AML cells. Such inhibitory effects correlated with dose-dependent suppression of cellular viability and leukemic progenitor colony formation. Moreover, combination of Tomivosertib and Venetoclax resulted in synergistic anti-leukemic responses in AML cell lines. Mass spectrometry studies identified novel putative MNK1/2 interactors, while in parallel studies we demonstrated that MNK2 - RAPTOR - mTOR complexes are not disrupted by Tomivosertib. Overall, these findings demonstrate that Tomivosertib exhibits potent anti-leukemic properties on AML cells and support the development of clinical translational efforts involving the use of this drug, alone or in combination with other therapies for the treatment of AML.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27952

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Inhibitory effects of Tomivosertib in acute myeloid leukemia

Abstract